Singular Research Reiterates “Buy-Venture” Rating for FSD Pharma (NASDAQ:HUGE)

FSD Pharma (NASDAQ:HUGE)‘s stock had its “buy-venture” rating restated by stock analysts at Singular Research in a research note issued to investors on Tuesday, Zacks.com reports. Singular Research also issued estimates for FSD Pharma’s Q1 2024 earnings at ($0.05) EPS, Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.12) EPS.

FSD Pharma Price Performance

Shares of HUGE stock opened at $0.35 on Tuesday. The stock has a market capitalization of $13.97 million, a PE ratio of -0.74 and a beta of 0.71. The business’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.86. FSD Pharma has a one year low of $0.34 and a one year high of $1.68.

FSD Pharma (NASDAQ:HUGE) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.04) EPS for the quarter.

Institutional Investors Weigh In On FSD Pharma

A hedge fund recently bought a new stake in FSD Pharma stock. Scotia Capital Inc. bought a new stake in FSD Pharma Inc. (NASDAQ:HUGE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 61,273 shares of the company’s stock, valued at approximately $55,000. Scotia Capital Inc. owned approximately 0.16% of FSD Pharma at the end of the most recent reporting period. 1.24% of the stock is owned by institutional investors and hedge funds.

FSD Pharma Company Profile

FSD Pharma Inc, a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.